Literature DB >> 29119252

Image-based surgical risk factors for Wilms tumor.

Takaharu Oue1, Akihiro Yoneda2, Noriaki Usui3, Takashi Sasaki4, Masahiro Zenitani4, Natsumi Tanaka4, Shuichiro Uehara2, Soji Ibuka3, Yuichi Takama5, Hiroomi Okuyama5.   

Abstract

PURPOSE: The standard treatment for Wilms tumor (WT) is primary resection. However, in cases with unresectable tumor or tumor spillage, which are considered to have high surgical risks, more intensive chemotherapy and radiotherapy are required. In the present study, we retrospectively analyzed preoperative image parameters to identify factors associated with surgical risks.
METHODS: Twenty-nine patients with WT were enrolled in this study. Data on various preoperative image parameters, such as tumor size, tumor volume, displacement of great vessels, and contralateral extension of the tumor were collected, and their relationship with surgical factors, including operative time, hemorrhage, tumor spillage, and unresectability were analyzed.
RESULTS: Patients with unresectable tumor or with tumor spillage (surgical high-risk group) more frequently demonstrated displacement of great vessels and contralateral tumor extension. Operative time and blood loss were also significantly related to tumor size, area, volume, displacement of great vessels and contralateral extension.
CONCLUSION: Besides tumor size, displacement of great vessels and contralateral extension were significantly associated with surgical risks. These factors are easily determined using CT images and are, therefore, useful to decide whether preoperative chemotherapy should be started instead of primary tumor resection for large localized WTs.

Entities:  

Keywords:  Contralateral extension; Displacement of great vessels; Surgical risk; Tumor size; Wilms tumor

Mesh:

Year:  2017        PMID: 29119252     DOI: 10.1007/s00383-017-4210-4

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  14 in total

1.  Surgical complications after primary nephrectomy for Wilms' tumor: report from the National Wilms' Tumor Study Group.

Authors:  M L Ritchey; R C Shamberger; G Haase; J Horwitz; T Bergemann; N E Breslow
Journal:  J Am Coll Surg       Date:  2001-01       Impact factor: 6.113

2.  Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial.

Authors:  J de Kraker; N Graf; H van Tinteren; F Pein; B Sandstedt; J Godzinski; M F Tournade
Journal:  Lancet       Date:  2004 Oct 2-8       Impact factor: 79.321

3.  Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group.

Authors:  Christopher Mitchell; Kathy Pritchard-Jones; Rosemary Shannon; Carolyn Hutton; Suzanne Stevens; David Machin; John Imeson; Anna Kelsey; Gordan M Vujanic; Peter Gornall; Jenny Walker; Roger Taylor; Pat Sartori; Juliet Hale; Gill Levitt; Boo Messahel; Helen Middleton; Richard Grundy; Jon Pritchard
Journal:  Eur J Cancer       Date:  2006-08-10       Impact factor: 9.162

4.  Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH.

Authors:  A Weirich; I Leuschner; D Harms; G M Vujanic; J Tröger; U Abel; N Graf; D Schmidt; R Ludwig; P A Voûte
Journal:  Ann Oncol       Date:  2001-03       Impact factor: 32.976

5.  Predictive factor for intraoperative tumor rupture of Wilms tumor.

Authors:  Hiroaki Fukuzawa; Yuko Shiima; Yasuhiko Mishima; Sachi Sekine; Shizu Miura; Kiyoaki Yabe; Satoshi Yamaki; Keiichi Morita; Yuichi Okata; Chieko Hisamatsu; Makoto Nakao; Akiko Yokoi; Kosaku Maeda; Yoshiyuki Kosaka
Journal:  Pediatr Surg Int       Date:  2016-11-01       Impact factor: 1.827

6.  Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study.

Authors:  G J D'Angio; N Breslow; J B Beckwith; A Evans; H Baum; A deLorimier; D Fernbach; E Hrabovsky; B Jones; P Kelalis
Journal:  Cancer       Date:  1989-07-15       Impact factor: 6.860

7.  Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4.

Authors:  R C Shamberger; K A Guthrie; M L Ritchey; G M Haase; J Takashima; J B Beckwith; G J D'Angio; D M Green; N E Breslow
Journal:  Ann Surg       Date:  1999-02       Impact factor: 12.969

8.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

Authors:  Susan L Cohn; Andrew D J Pearson; Wendy B London; Tom Monclair; Peter F Ambros; Garrett M Brodeur; Andreas Faldum; Barbara Hero; Tomoko Iehara; David Machin; Veronique Mosseri; Thorsten Simon; Alberto Garaventa; Victoria Castel; Katherine K Matthay
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

9.  Primary nephrectomy and intraoperative tumor spill: report from the Children's Oncology Group (COG) renal tumors committee.

Authors:  Kenneth W Gow; Douglas C Barnhart; Thomas E Hamilton; Jessica J Kandel; Mike K S Chen; Fernando A Ferrer; Mitchell R Price; Elizabeth A Mullen; James I Geller; Eric J Gratias; Nancy Rosen; Geetika Khanna; Arlene Naranjo; Michael L Ritchey; Paul E Grundy; Jeffrey S Dome; Peter F Ehrlich
Journal:  J Pediatr Surg       Date:  2013-01       Impact factor: 2.545

10.  Outcome of pediatric renal tumor treated using the Japan Wilms Tumor Study-1 (JWiTS-1) protocol: a report from the JWiTS group.

Authors:  Takaharu Oue; Masahiro Fukuzawa; Hajime Okita; Hideo Mugishima; Hiroshi Horie; Jun-ichi Hata; Masahiro Saito; Miwako Nozaki; Motoaki Chin; Hisaya Nakadate; Shiro Hinotsu; Tsugumichi Koshinaga; Yasuhiko Kaneko; Yoshihiro Kitano; Yukichi Tanaka
Journal:  Pediatr Surg Int       Date:  2009-11       Impact factor: 1.827

View more
  1 in total

1.  Factors responsible for stage III disease in patients with Wilms tumor enrolled in the JWiTS-2 study.

Authors:  Takaharu Oue; Koji Fukumoto; Ryota Souzaki; Tetsuya Takimoto; Tsugumichi Koshinaga
Journal:  Pediatr Surg Int       Date:  2019-08-08       Impact factor: 1.827

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.